What is the official website of BOTOX® Cosmetic (onabotulinumtoxinA) ?

The official website of BOTOX® Cosmetic (onabotulinumtoxinA) is https://hcp.botoxcosmetic.com/.

What is BOTOX® Cosmetic (onabotulinumtoxinA)'s cybersecurity risk score?

BOTOX® Cosmetic (onabotulinumtoxinA) has an AI-generated cybersecurity risk score of 754 out of 1000, indicating a Fair security posture according to Rankiteo's assessment.

How many security incidents has BOTOX® Cosmetic (onabotulinumtoxinA) experienced?

According to Rankiteo, BOTOX® Cosmetic (onabotulinumtoxinA) currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has BOTOX® Cosmetic (onabotulinumtoxinA) been affected by any supply chain cyber incidents ?

According to Rankiteo, BOTOX® Cosmetic (onabotulinumtoxinA) has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does BOTOX® Cosmetic (onabotulinumtoxinA) have SOC 2 Type 1 certification ?

According to Rankiteo, BOTOX® Cosmetic (onabotulinumtoxinA) is not certified under SOC 2 Type 1.

Does BOTOX® Cosmetic (onabotulinumtoxinA) have SOC 2 Type 2 certification ?

According to Rankiteo, BOTOX® Cosmetic (onabotulinumtoxinA) does not hold a SOC 2 Type 2 certification.

Does BOTOX® Cosmetic (onabotulinumtoxinA) comply with GDPR ?

According to Rankiteo, BOTOX® Cosmetic (onabotulinumtoxinA) is not listed as GDPR compliant.

Does BOTOX® Cosmetic (onabotulinumtoxinA) have PCI DSS certification ?

According to Rankiteo, BOTOX® Cosmetic (onabotulinumtoxinA) does not currently maintain PCI DSS compliance.

Does BOTOX® Cosmetic (onabotulinumtoxinA) comply with HIPAA ?

According to Rankiteo, BOTOX® Cosmetic (onabotulinumtoxinA) is not compliant with HIPAA regulations.

Does BOTOX® Cosmetic (onabotulinumtoxinA) have ISO 27001 certification ?

According to Rankiteo,BOTOX® Cosmetic (onabotulinumtoxinA) is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does BOTOX® Cosmetic (onabotulinumtoxinA) operate in ?

BOTOX® Cosmetic (onabotulinumtoxinA) operates primarily in the Pharmaceutical Manufacturing industry.

How many employees does BOTOX® Cosmetic (onabotulinumtoxinA) have ?

BOTOX® Cosmetic (onabotulinumtoxinA) employs approximately 0 people worldwide.

Does BOTOX® Cosmetic (onabotulinumtoxinA) own any subsidiaries ?

BOTOX® Cosmetic (onabotulinumtoxinA) presently has no subsidiaries across any sectors.

How many LinkedIn followers does BOTOX® Cosmetic (onabotulinumtoxinA) have ?

BOTOX® Cosmetic (onabotulinumtoxinA)'s official LinkedIn profile has approximately 2,415 followers.

What is the NAICS classification code for BOTOX® Cosmetic (onabotulinumtoxinA) ?

BOTOX® Cosmetic (onabotulinumtoxinA) is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.

Does BOTOX® Cosmetic (onabotulinumtoxinA) have a Crunchbase profile ?

No, BOTOX® Cosmetic (onabotulinumtoxinA) does not have a profile on Crunchbase.

Does BOTOX® Cosmetic (onabotulinumtoxinA) have a LinkedIn profile ?

Yes, BOTOX® Cosmetic (onabotulinumtoxinA) maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/botox-cosmetic-usa.

How many cybersecurity incidents has BOTOX® Cosmetic (onabotulinumtoxinA) experienced ?

As of June 10, 2026, Rankiteo reports that BOTOX® Cosmetic (onabotulinumtoxinA) has experienced 2 cybersecurity incidents.

How many peer or competitor companies does BOTOX® Cosmetic (onabotulinumtoxinA) have ?

BOTOX® Cosmetic (onabotulinumtoxinA) has an estimated 5,683 peer or competitor companies worldwide.

What types of cybersecurity incidents has BOTOX® Cosmetic (onabotulinumtoxinA) faced ?

Incident Types: The types of cybersecurity incidents that have occurred include Breach and Vulnerability.

NEWRankiteo Cyber Underwriting Desktop - Score, price, and bind from your desktop

WindowsmacOSLinux

Download

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

Boost Score +25 with badge (5 left)

754

/1000

Fair

779

/1000

Fair

BOTOX® Cosmetic (onabotulinumtoxinA) Vendor Cyber Rating & Cyber Score

botoxcosmetic.com

Add Your Compliance Badge

Please see Prescribing Information and Important Safety Information, including Boxed Warning, below. A leader in aesthetic neurotoxins for decades, BOTOX® Cosmetic is the only neurotoxin that’s FDA approved for simultaneous treatment in adults for 3 areas of the face: to temporarily improve the appearance of moderate to severe forehead line, lateral canthal lines, and glabellar lines.1-5 Follow our page to learn how BOTOX® Cosmetic can support you and your patients. REFERENCES: 1. BOTOX® Cosmetic Prescribing Information, July 2020. 2. Dysport® Prescribing Information, January 2023. 3. Xeomin® Prescribing Information, August 2021. 4. Jeuveau® Prescribing Information, January 2020. 5. Daaxify™ Prescribing Information, September 2022.

BC A.I CyberSecurity Scoring

Scoring History

BOTOX® Cosmetic (onabotulinumtoxinA) CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

AbbVie

Vulnerability

100

4/2026

EGAABB177565877...

BOTOX® Cosmetic (on...

Breach

100

6/2023

ABB0473723

Loading…

A.I.

BC Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for BC

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for BOTOX® Cosmetic (onabotulinumtoxinA) in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for BOTOX® Cosmetic (onabotulinumtoxinA) in 2026.

Incident Types BC vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for BOTOX® Cosmetic (onabotulinumtoxinA) in 2026.

Incident History - BC (X = Date, Y = Severity)

Loading…

SUBSIDIARY

BOTOX® Cosmetic (onabotulinumtoxinA) Subsidiaries

BC

Pharmaceutical Manufacturing

Website: https://hcp.botoxcosmetic.com/

Company Size: 0

AbbViePharmaceutical Manufacturing

AbbVie | ImmunologyPharmaceutical Manufacturing

AbbVie | OncologyPharmaceutical Manufacturing

AbbVie | UKPharmaceutical Manufacturing

AbbVie | NeurosciencePharmaceutical Manufacturing

AbbVie | FrancePharmaceutical Manufacturing

Eye CarePharmaceutical Manufacturing

Pharmacyclics, an AbbVie CompanyPharmaceutical Manufacturing

AbbVieEyetoEyePharmaceutical Manufacturing

AbbVie | VirologyPharmaceutical Manufacturing

AbbVie | EspañaPharmaceutical Manufacturing

AbbVie | AustraliaPharmaceutical Manufacturing

AbbVie Contract ManufacturingPharmaceutical Manufacturing

AbbVieEyetoEyePharmaceutical Manufacturing

Natrelle Breast ImplantsPharmaceutical Manufacturing

Allergan Aesthetics Plastic and Regenerative Medicine PortfolioMedical Equipment Manufacturing

Allergan Medical InstitutePharmaceutical Manufacturing

Allergan Aesthetics, an AbbVie CompanyPharmaceutical Manufacturing

Loading…

BOTOX® Cosmetic (onabotulinumtoxinA) Similar Companies

Johnson & Johnson Innovative Medicine

cb jnj.com

At Johnson & Johnson Innovative Medicine, we innovate with purpose, to lead where medicine is going. The experiences of patients around the world inform and inspire our science-based innovations, which continue to change and save lives. Applying rigorous science with compassion, we confidently address the most complex diseases of our time and develop the potential medicines of tomorrow. We are continuously working to develop treatments, aspiring to find cures, pioneering the path from lab to life, and championing patients every step of the way. https://bit.ly/3reuMvK

Novartis

cb novartis.com

Novartis is an innovative medicines company. Every day, working to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide. Find out more at https://www.novartis.com See our community guidelines: https://go.novartis.social/3Nboxki

Novo Nordisk

novonordisk.com

We’re not your typical healthcare company. In a modern world of quick fixes, we focus on solutions to defeat serious chronic disease and create long-term health. Our unordinary mindset is at the heart of everything we do. We seek out new ideas and put people first as we push the boundaries of science, make healthcare more accessible, and work to treat, prevent, and even cure diseases that affect millions of lives. Founded in Denmark in 1923, today we employ more than 77,000 people in 80 offices around the world – all united by our bold purpose to drive change to defeat serious chronic diseases. Want to learn more? Visit www.novonordisk.com. This page isn’t intended for discussions about products. As such, postings or comments that contain product discussions may be removed. This page is for discussions about Novo Nordisk and its subsidiaries and the initiatives and projects we are involved in. While we welcome everyone to make comments, we reserve the right to block and remove those that are off-topic, abusive or intended to spam. Any questions specific to products should be made to your healthcare professional. If you wish to file an adverse drug reaction please contact Novo Nordisk’s office in the country you live in: https://www.novonordisk.com/contact-us/find-local-information.html For other customer complaints, please contact us here: https://www.novonordisk.com/contact-us.html Please keep in mind that Novo Nordisk A/S and its subsidiaries work within a highly regulated industry. Therefore, comments that pertain to legal matters or regulatory issues may be removed. Comments contained on this site come from members of the public, and do not necessarily reflect the views of Novo Nordisk A/S. Novo Nordisk A/S does not endorse or approve any content added by other LinkedIn users. Learn more about our privacy disclaimer and community guidelines here: https://www.novonordisk.com/data-privacy-and-user-rights/social-media-privacy-disclaimer.html

Grifols

cb linktr.ee

Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people all over the world. A leader in essential plasma-derived medicines and transfusion medicine, we develop, produce and provide innovative healthcare services and solutions in more than 110 countries. Patient needs and our ever-growing knowledge of many chronic, rare and prevalent diseases, sometimes life-threatening, drive our innovation in plasma-based therapies and other biopharmaceuticals to enhance quality of life. Grifols is focused on treating conditions across a broad range of therapeutic areas: immunology, hepatology and intensive care, pulmonology, hematology, neurology and infectious diseases. With a workforce of over 23,000 employees in more than 30 countries and regions, we are committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership in the industry. Our work has a positive social and economic impact in the countries where we operate, creating jobs and generating wealth. People are at the heart of what we do, and we strive to create an inclusive, diverse, fair and equal society. Maintaining and promoting a workforce that reflects this reality leads to enhanced professional relationships and helps us to give our best to patients, donors and customers. In 2024, Grifols was named one of TIME’s ‘World’s Best Companies’ for the second year in a row, reaffirming our commitment to excellence. We were also recognized by Forbes as one of the "Best Employers for Women 2023," reflecting our dedication to fostering an inclusive and supportive workplace for all. To maintain a positive community and overall respectful communication, please keep our community guidelines in mind.

Zoetis

zoetis.com

The world’s leading animal health company. We’ve been innovating ways to predict, prevent, detect, and treat animal illness for over 70 years, and we continue to stand by those raising and caring for animals worldwide – from veterinarians and pet owners to livestock farmers. Our leading portfolio and pipeline makes a difference in over 100 countries. Community Guidelines: This page is intended to share how Zoetis is advancing care for animals. We aspire to create a supportive community, but there are guidelines to which posts and comments on this page must adhere. If your post references a side effect related to any Zoetis product, we may contact you for more information. To monitor the safety of Zoetis products, we advise you to call our Veterinary Medical Information and Product Support Team at 1-888-963-8471; Support Team is available Mon-Fri 9am to 6:30pm ET. We reserve the right to remove any post/comment that violates LinkedIn Guidelines. As a last resort, we reserve the right to block users that demonstrate a repeated pattern of violating LinkedIn’s spirit of constructive, professional discourse. We respectfully request that you refrain from posting comments including: Unsolicited and/or unverified medical advice Vulgarity and/or profanity Discriminatory and/or derogatory comments, hate speech Politics and religion Personal attacks and/or threats Promotion of illegal activity Copyright/trademark infringements Topics that may be considered spam/advertising Our regular business hours are Mon-Fri 9am to 5pm ET. Zoetis does not endorse and is not responsible for information and opinions shared by community members. The information shared is provided for educational purposes only and is not intended to replace discussions with an animal healthcare professional. Testimonials represent individual experience only and the experiences and opinions of community members may be unique to the speaker. Terms of Use: https://www.zoetis.com/terms-of-use

Lonza

lonza.com

Lonza is a pioneer and world leader in the CDMO industry, setting the pace with cutting-edge science, smart technology, and lean manufacturing. United by a common purpose, we turn our customers’ breakthrough innovations into viable therapies and manufacture the medicines of tomorrow. Founded in Switzerland in 1897, our company is the first and original CDMO, and today we are more dynamic, agile and forward-focused than ever before. As one of the largest Western CDMOs, we bring together a global team of around 18,500 colleagues across five continents to deliver comprehensive, integrated solutions for our customers' complex needs. For our customers and their patients, we bring quality, safety and reliability to bring life-enhancing and life-saving treatments to market at speed and at scale. For our colleagues, we strive to create a sense of belonging and inclusion where every person can thrive and bring their best.

Sanofi

sanofi.com

We are an R&D driven, AI-powered biopharma company committed to improving people’s lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people’s lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time. Interactions with this account must comply with the Terms: https://bit.ly/sanofi-terms

Torrent Pharmaceuticals Ltd

cb torrentpharma.com

Torrent Pharma, with annual revenues of more than Rs 10,700 crores, is the flagship Company of the Torrent Group, with group revenues of Rs 41,000 crores. It is ranked 5th in the Indian Pharma Market and is among the Top 5 in the therapeutic segments of Cardiovascular (CV), Central Nervous System (CNS), Gastro-intestinal (GI), Vitamins Minerals Nutritionals (VMN) and Cosmo-Dermatology. The Company also has significant presence in diabetology, pain management, gynaecology, oncology and anti-infective segments. Torrent has 8 manufacturing facilities , of which 5 are USFDA approved. With R&D as the backbone for its growth in domestic & overseas market, it has invested significantly in R&D capabilities with state-of-the-art R&D infrastructure employing around 800 scientists. The acquisition of Elder Pharma's Indian branded business in 2013, Dermaceuticals business of Zyg Pharma in 2015, API plant of Glochem Industries in 2016, Women healthcare brands from Novartis and Unichem's Indian branded business along with its Sikkim Plant in 2017 strengthened Torrent Pharma's position in the Indian Pharma market. Torrent Pharma started international acquisitions in 2005 with entry into the German market. Today, the Company has presence in more than 50 countries and is ranked No. 1 among the Indian pharma Companies in Brazil and Germany. Torrent Pharma is committed towards “not just healthcare but lifecare.”

Astellas Pharma

astellas.com

Astellas is a global life sciences company committed to turning innovative science into VALUE for patients. We provide transformative therapies in disease areas that include oncology, ophthalmology, urology, immunology and women's health. Through our research and development programs, we are pioneering new healthcare solutions for diseases with high unmet medical need. Visit our Global Astellas LinkedIn Community Guidelines to learn more about interacting with this page: https://www.astellas.com/en/global-linkedin-community-guidelines

Loading…

NEWS

BOTOX® Cosmetic (onabotulinumtoxinA) CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

September 09, 2025 07:00 AM

BOTOX® Cosmetic (onabotulinumtoxinA) Unveils "The One & Only" Campaign Featuring Real People and Their Distinctive Stories

Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today announced a new chapter for BOTOX® Cosmetic with the debut of "The One & Only"...

Read Article

June 24, 2024 07:00 AM

How to spot fake Botox, or 'Faux-Tox,' and other skincare dupes and beauty counterfeit knockoffs

Fake Botox, skincare dupes and counterfeit cosmetics are not only impacting wallets, but can also pose major health concerns.

Read Article

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-9754

SUMMARY

An authenticated user with the read role may read limited amounts of uninitialized stack memory via specially-crafted issuances of the filemd5 command

Published

Date2026-06-09

Updated

Date2026-06-09

RISK INFORMATION (Score: 6.5)

cvss3

Base Score: 6.5

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:H/I:N/A:N

cvss4

Base Score: 7.1

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:N/VC:H/VI:N/VA:N/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

3.6

Exploitability

2.8

REFERENCES

https://jira.mongodb.org/browse/SERVER-122207

CVE-2026-9753

SUMMARY

The $_internalApplyOplogUpdate aggregation pipeline stage can be used to execute a document diff containing a malformed binary diff to return memory out-of-bounds or crash the server. $_internalApplyOplogUpdate can be executed by any authenticated user with access to the aggregate command.

Published

Date2026-06-09

Updated

Date2026-06-09

RISK INFORMATION (Score: 8.1)

cvss3

Base Score: 8.1

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:H/I:N/A:H

cvss4

Base Score: 7.2

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:N/VC:H/VI:N/VA:H/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

5.2

Exploitability

2.8

REFERENCES

https://jira.mongodb.org/browse/SERVER-124959

CVE-2026-9752

SUMMARY

An authorized user could trigger a server crash by running a query with a 2dsphere index on a field that stores a GeoJSON GeometryCollection containing a Polygon with a strict-winding CRS. Strict-winding polygons are intentionally unsupported for indexing, but the guard that rejects them does not inspect members of a GeometryCollection, allowing the unsafe path to be reached which ends with an ensuing null-pointer dereference.

Published

Date2026-06-09

Updated

Date2026-06-09

RISK INFORMATION (Score: 6.5)

cvss3

Base Score: 6.5

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:N/I:N/A:H

cvss4

Base Score: 7.1

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:N/VC:N/VI:N/VA:H/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

3.6

Exploitability

2.8

REFERENCES

https://jira.mongodb.org/browse/SERVER-123440

CVE-2026-9751

SUMMARY

The ldapQueryPassword parameter, when set through the runtime setParameter command, will log the new password to the mongod.log file in plain text.

Published

Date2026-06-09

Updated

Date2026-06-09

RISK INFORMATION (Score: 5.5)

cvss3

Base Score: 5.5

Complexity: LOW

CVSS:3.1/AV:L/AC:L/PR:L/UI:N/S:U/C:H/I:N/A:N

cvss4

Base Score: 6.8

Complexity: LOW

CVSS:4.0/AV:L/AC:L/AT:N/PR:L/UI:N/VC:H/VI:N/VA:N/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

3.6

Exploitability

1.8

REFERENCES

https://jira.mongodb.org/browse/SERVER-123370

CVE-2026-9750

SUMMARY

An authenticated user can cause a MongoDB server to crash or return incorrect results by creating documents that interfere with internal metadata processing during query execution. This stems from insufficient separation between user-controlled document fields and internal metadata in certain execution paths.

Published

Date2026-06-09

Updated

Date2026-06-09

RISK INFORMATION (Score: 6.5)

cvss3

Base Score: 6.5

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:N/I:N/A:H

cvss4

Base Score: 7.1

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:N/VC:N/VI:N/VA:H/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

3.6

Exploitability

2.8

REFERENCES

https://jira.mongodb.org/browse/SERVER-123633

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…